Difference between revisions of "Team:NCTU Formosa"

 
Line 220: Line 220:
 
        <div class="photocontent1"><h2>What we care about</h2>
 
        <div class="photocontent1"><h2>What we care about</h2>
 
         
 
         
−
In 2015, we focused on helping doctors select appropriate candidates for monoclonal-antibody targeted drug treatments—reducing the price of patients' treatment. If the cost for diagnosis decreases, more patients can afford it lowering the mortality rate of cancer. <br>
+
In 2015, we focused on helping doctors select appropriate candidates for monoclonal-antibody targeted drug treatments—reducing the price of patients' treatment. If the cost for diagnosis decreases, more patients can afford it. Therefore lowering the mortality rate of cancer. <br>
 
             </div>
 
             </div>
 
      </div>
 
      </div>

Latest revision as of 02:41, 19 September 2015

The only thing we can detect is everything.

Who we are

NCTU_Formosa created an organization—APOllO, which stands for Almighty Probe of scFv Organization. APOllO is devoted to developing detection technology by utilizing antibodies. In 2015, we cooperated with iGEM to create a brand new detection platform using synthetic biology.

What's new

APOllO E.Cotector:
Our organization creates a customized scFv detection platform by co-transforming any desired plasmid in to E. coli. ScFv utilizes antigen-antibody interaction to act as probes. Therefore, our E.Cotector has the function of a detector.

What we care about

In 2015, we focused on helping doctors select appropriate candidates for monoclonal-antibody targeted drug treatments—reducing the price of patients' treatment. If the cost for diagnosis decreases, more patients can afford it. Therefore lowering the mortality rate of cancer.